Erratum: Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma (Oncogene (2010) 29 (3228-3240) DOI: 10.1038/onc.2010.71);Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma

Oncogene

Volumn 29, Issue 22, 2010, Pages 3228-3240

  Kang, J ^a   Qian, P X ^b   Pandey, V ^a   Perry, J K ^a   Miller, L D ^c   Liu, E T ^d   Zhu, T ^b   Liu, D X ^a   Lobie, P E ^a,e  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d GENOME INSTITUTE OF SINGAPORE   (Singapore)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Antiestrogen resistance; Artemin; Mammary carcinoma

Indexed keywords

ANTIESTROGEN; ARTEMIN; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; PROTEIN BCL 2; SMALL INTERFERING RNA; TAMOXIFEN; ARTN PROTEIN, HUMAN; ESTRADIOL; NERVE PROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADJUVANT CHEMOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; META ANALYSIS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; NERVE TISSUE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; RNA, SMALL INTERFERING; TAMOXIFEN; TRANSCRIPTION, GENETIC;

EID: 77953230502     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.553     Document Type: Erratum

References (63)

1. Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Nomura Y et al. (1998). Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467.
2. Airaksinen MS, Saarma M. (2002). The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3: 383-394.
3. Arpino G, Wiechmann L, Osborne CK, Schiff R. (2008). Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29: 217-233.
4. Baloh RH, Tansey MG, Lampe PA, Fahrner TJ, Enomoto H, Simburger KS et al. (1998). Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRa3-RET receptor complex. Neuron 21: 1291-1302.
5. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. (2004). Loss of ER beta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 11: 537-551.
6. Boulay A, Breuleux M, Stephan C, Fux C, Brisken C, Fiche M et al. (2008). The ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer. Cancer Res 68: 3743-3751.
7. Bursch W, Ellinger A, Kienzl H, Tarak L, Pandey S, Sikorska M et al. (1996). Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. Carcinogenesis 17: 1595-1607.
8. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. (2001). Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276: 9817-9824.
9. Carmillo P, Dag0 L, Day ES, Worley DS, Rossomando A, Walus L et al. (2005). Glial cell line-derived neurotrophic factor (GDNF) receptor a-1 (GFRa1) is highly selective for GDNF versus artemin. J Biol Chem 44: 2545-2554.
10. Chung YL, Sheu ML, Yang SC, Lin CH, Yen SH. (2002). Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int J Cancer 97: 306-312.
11. Diel P, Smolnikar K, Michna H. (1999). The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells. Breast Cancer Res Treat 58: 87-97.
12. Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA, Sutherland RL. (2003). Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 10: 179-186.
13. Dowsett M, Nicholson RI, Pietras RJ. (2005). Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Res Treat 93: S11-S18.
14. Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC et al. (1997). bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group Study. J Clin Oncol 15: 1916-1922.
15. Fagan DH, Yee D. (2008). Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 13: 423-429.
16. Hall JM, McDonnel DP. (1999). The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140: 5566-5578.
17. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J et al. (2007). Estrogen receptors: how do they signal and what are their targets. Physiol Rev 87: 905-931.
18. Hodges-Gallagher L, Valentine CD, Bader SE, Kushner PJ. (2008). Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells. Breast Cancer Res Treat 109: 241-250.
19. Johnston SRD. (2005). Selective oestrogen receptor modulators and downregulators for breast cancer\have they lost their way? Breast Cancer Res 7: 119-130.
20. Kampa M, Pelekanou V, Castanas E. (2008). Membrane-initiated steroid action in breast and prostate cancer. Steroids 73: 953-960.
21. Kang J, Perry JK, Pandey V, Fielder GC, Mei B, Qian PX et al. (2009). Artemin is oncogenic for human mammary carcinoma cells. Oncogene 28: 2034-2045.
22. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H et al. (1995). Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491-1494.
23. Ke N, Albers A, Claassen G, Yu DH, Chatterton JE, Hu X et al. (2004). One-week 96-well soft agar growth assay for cancer target validation. Biotechniques 36: 826-833.
24. Kim R, Tanabe K, Emi M, Uchida Y, Toge T. (2005). Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells. Cancer 103: 2199-2207.
25. Knowlden JM, Hutcheson IR, Barrow D, Gee JMW, Nicholson RI. (2005). Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology 146: 4609-4618.
26. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JMW, Harper ME et al. (2003). Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144: 1032-1044.
27. Kumar R, Mandal M, Lipton A, Harvey H, Thompson CB. (1996). Overexpression of HER2 modulates bcl-2, Bcl-X(L) and tamoxifen induced apoptosis in human MCF-7 breast cancer cells. Clin Cancer Res 2: 1215-1219. (Pubitemid 26238454)
28. Lee GY, Kenny PA, Lee EH, Bissell MJ. (2007). Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 4: 359-365.
29. Levin ER, Pietras RJ. (2008). Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat 108: 351-361.
30. Liu DX, Lobie PE. (2007). Transcriptional activation of p53 by Pitx1. Cell Death Differ 14: 1893-1907.
31. Mandlekar S, Kong ANT. (2001). Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6: 469-477.
32. Marino M, Galluzzo P, Ascenzi P. (2006). Estrogen signaling multiple pathways to impact gene transcription. Curr Genomics 7: 497-508.
33. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S et al. (2008). Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68: 826-833.
34. Massarweh S, Schiff R. (2006). Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer 13: S15-S24.
35. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM et al. (2001). Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142: 2776-2788.
36. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A et al. (2005). An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102: 13550-13555.
37. Murphy LC, Watson PH. (2006). Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer? Endocr Relat Cancer 13: 327-334.
38. Musgrove EA, Sutherland RL. (2009). Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9: 631-643.
39. Nicholson RI, Hutcheson IR, Hiscox SE, Knowlden JM, Giles M, Barrow D et al. (2005). Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr Relat Cancer 12: S29-S36.
40. Nicholson RI, Hutcheson IR, Jones HE, Hiscox SE, Giles M, Taylor KM et al. (2007). Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. Rev Endocr Metabol Disord 8: 241-253.
41. O'Neill PA, Davies MPA, Shaaban AM, Innes H, Torevell A, Sibson DR et al. (2004). Wild-type oestrogen receptor beta mRNA and protein expression in tamoxifen-treated post-menopausal breast cancers. Br J Cancer 91: 1694-1702.
42. Osborne CK. (1998). Tamoxifen in the treatment of breast cancer. N Engl J Med 339: 1609-1618.
43. Pandey V, Perry JK, Mohankumar KM, Kong XJ, Liu SM, Wu ZS et al. (2008). Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells. Endocrinology 149: 3909-3919.
44. Pandey V, Qian PX, Kang J, Perry JK, Mitchell MD, Yin ZN et al. (2010). Artemin stimulates oncogenicity and invasiveness of endometrial carcinoma cells. Endocrinology 151: 909-920.
45. Park BW, Kim KS, Heo MK, Ko SS, Hong SW, Yang WI et al. (2003). Expression of estrogen receptor-beta in normal mammary and tumor tissues: is it protective in breast carcinogenesis? Breast Cancer Res Treat 80: 79-85.
46. Perillo B, Sasso A, Abbondanza C, Palumbo G. (2000). 17B-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 20: 2890-2901.
47. Pettersson K, Delaunay F, Gustafsson JA. (2000). Estrogen receptor beta acts as a dominant regulator of estrogen signaling. Oncogene 19: 4970-4978.
48. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. (2007). Pathways to tamoxifen resistance. Cancer Lett 256: 1-24.
49. Riggins RB, Zwart A, Nehra R, Clarke R. (2005). The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Mol Cancer Ther 4: 33-41.
50. Rody A, Holtrich U, Solbach C, Kourtis K, Von Minckwitz G, Engels K et al. (2005). Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer 12: 903-916.
51. Rotolo S, Ceccarelli S, Romano F, Frati L, Marchese C, Angeloni A. (2008). Silencing of keratinocyte growth factor receptor restores 5-fluorouracil and tamoxifen efficacy on responsive cancer cells. PLoS ONE 3: e2528.
52. Sarkaria JN, Gibson DFC, Jordan VC, Fowler JF, Lindstrom MJ, Mulcahy RT. (1993). Tamoxifen-induced increase in the potential doubling time of MCF-7 xenografts as determined by bromodeoxyuridine labeling and flow cytometry. Cancer Res 53: 4413-4417.
53. Shaaban AM, O'Neill PA, Davies MPA, Sibson R, West CR, Smith PH et al. (2003). Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol 27: 1502-1512.
54. Shaw LE, Sadler AJ, Pugazhendhi D, Darbre PD. (2006). Changes in oestrogen receptor-alpha and-beta during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells. J Steroid Biochem Mol Biol 99: 19-32.
55. Siddiqa A, Long LM, Li L, Marciniak RA, Kazhdan I. (2008). Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways. BMC Cancer 8: 129.
56. Speirs V, Malone C, Walton DS, Kerin MJ, Atkin SL. (1999). Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res 59: 5421-5424.
57. Tangkeangsirisin W, Hayashi J, Serrero G. (2004). PC cell-derived growth factor mediates tamoxifen resistance and promotes tumor growth of human breast cancer cells. Cancer Res 64: 1737-1743.
58. Teixeira C, Reed JC, Pratt MAC. (1995). Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55: 3902-3907.
59. Williams C, Edvardsson K, Lewandowski SA, Stram A, Gustafsson JA. (2008). A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene 27: 1019-1032.
60. Yager JD, Davidson NE. (2006). Estrogen carcinogenesis in breast cancer. N Engl J Med 354: 270-282.
61. Zhang GJ, Kimijima I, Onda M, Kanno M, Sato H, Watanabe T et al. (1999). Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels. Clin Cancer Res 5: 2971-2977.
62. Zhang X, Zhu T, Chen Y, Mertani HC, Lee KO, Lobie PE. (2003). Human growth hormone-regulated HOXA1 is a human mammary epithelial oncogene. J Biol Chem 278: 7580-7590.
63. Zhu T, Emerald BS, Zhang X, Lee KO, Gluckman PD, Mertani HC et al. (2005). Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone. Cancer Res 65: 317-324.